



BioCorporate profile downloaded from - <http://www.bioportfolio.com> on Sunday, November 22, 2009

Bioclone Australia Pty Limited

[View the current Bioclone Australia Pty Limited Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/19438-Bioclone+Australia+Pty+Limited.html)

(<http://www.bioportfolio.com/biocorporate/19438-Bioclone+Australia+Pty+Limited.html>)

Contact Details:

**71-73 Railway Parade
Marrickville
New South Wales
NSW 2204
Australia**

Tel: 61 (0)2 9517 1966
Fax: 61 (0)2 9517 2990
Email: sales1@bioclone.com.au

Bioclone is an Australian-based subsidiary of Hitachi Chemical Co., Ltd., specialising in the manufacture of high quality immunodiagnostic products for the medical and research laboratory markets. Bioclone was formed in 1981 to take advantage of Australian expertise in medical research and biotechnology. A collaborative project between the CSIRO and the Garvan Institute for Medical Research gave Bioclone an excellent range of monoclonal antibodies to pituitary hormones from which diagnostic kits were later developed. Bioclone now produces Australia's largest range of immunoassay products for the medical diagnostics market. The products are marketed worldwide through a network of distributors. Bioclone has continued to invest in innovation and new product development both through collaboration with research organisations and through its own Research and Development team.

Press Releases on Bioclone Australia Pty Limited:

[XanGo and a Legion of More Than One Million Global Distributors Cheer on Real Salt Lake in Its Bid for MLS Cup](#)

20th November, 2009 XanGo, LLC

LEHI, Utah, Nov. 20 /PRNewswire/ -- This Sunday, when Major League Soccer's Real Salt Lake (RSL) takes on David Beckham, Landon Donovan and the star-studded Los Angeles Galaxy for the MLS Cup,

[Landauer, Inc. Sets Date and Time for Announcement of Fiscal Fourth Quarter and Full Year 2009 Results](#)

20th November, 2009 Landauer, Inc.

GLENWOOD, Ill., Nov. 20 /PRNewswire-FirstCall/ -- Landauer, Inc. (NYSE: LDR), will release financial results for the fiscal fourth quarter and full year of 2009 pre-market on Tuesday, December 1, 2009

Reportlinker Adds Power Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015	20th November, 2009	Reportlinker	NEW YORK, Nov. 20 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Power Wheelchair Market Shares, Strategies, and Forecasts, Worldwide,
Reportlinker Adds Toothpaste - Global Market Trends	20th November, 2009	Reportlinker	NEW YORK, Nov. 20 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Toothpaste - Global Market Trends http://www.reportlinker.com/p0164389
Reportlinker Adds Global Self Monitoring Blood Glucose Market (SMBG): Increasing Adoption to Drive Growth	20th November, 2009	Reportlinker	NEW YORK, Nov. 20 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Global Self Monitoring Blood Glucose Market (SMBG): Increasing Adoption to

BioNews Results for Bioclone Australia Pty Limited



- [Palm Oil Board achieves another first in oil palm genomes development](#)
TheStar.com.my: Nov 16 2009 12:14AM Matching: australia pty
- [Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor\(R\) i](#)
Pharmacy Choice: Nov 15 2009 2:33PM Matching: australia pty
- [ITL Limited - Pharmaceuticals & Healthcare - Deals and Alliances Profile - new report released](#)
PR inside: Nov 13 2009 5:29PM Matching: australia pty
- [Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor in A](#)
Pharmacy Choice: Nov 11 2009 3:36PM Matching: australia pty
- [AVG \(AU/NZ\) Again Wins Computer Troubleshooters' Vendor Of The Year Award](#)
Voxy.co.nz: Nov 6 2009 12:27AM Matching: australia pty
- [Starpharma enters agricultural chemicals market](#)
Business Spectator: Nov 5 2009 1:31PM Matching: australia pty
- [Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor in A](#)
Pharma Live: Nov 3 2009 4:30PM Matching: australia pty
- [Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor\(R\) i](#)
NewsBlaze: Oct 31 2009 11:35AM Matching: australia pty
- [Cumberland Pharma gets pain drug marketing partner](#)
Seattle Times: Oct 30 2009 12:41AM Matching: australia pty
- [Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor\(R\) i](#)
Therapeutics Daily: Oct 30 2009 1:42AM Matching: australia pty

- [Cumberland to sell new drug in Australia, New Zealand](#)
San Francisco Business Times: Oct 30 2009 1:39AM Matching: australia pty
- [Phebra signs commercialization agreement with Cumberland Pharmaceuticals for Caldolor\(R\) in Australia and New Zealand](#)
Quote.com Australia: Oct 30 2009 8:53PM Matching: australia pty
- [Cumberland Pharmaceuticals and Phebra team up to commercialize Caldolor injection](#)
News-Medical.Net: Oct 30 2009 4:04AM Matching: australia pty
- [Phebra signs commercialization agreement with Cumberland Pharmaceuticals for Caldolor\(R\) in Australia and New Zealand](#)
Individual.com: Oct 30 2009 7:49PM Matching: australia pty
- [Cumberland Pharma Gets Pain Drug Marketing Partner](#)
ABC News: Oct 29 2009 8:41PM Matching: australia pty

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10
Copyright 1997-2009 - BioPortfolio Limited.

